Background:Hereditary transthyretin (ATrRv) amyloidosis is an autosomal dominant disease linked to transthyretin gene mutations which cause instability of the transthyretin tetramer.After dissociation and misfolding they reassemble as insoluble fibrils (i.e.amyloid).Apart from the common Val30Met mutation there is a very heterogeneous group of non-Val30Met mutations.In some cases,the clinical picture is dominated by a rapidly evolving restrictive and hypertrophic cardiomyopathy.Methods:A case series of four liver recipients with the highly clinically relevant,rare and particularly ag-gressive Val122del mutation is presented.Medical and surgical therapeutic options,waiting list policy for ATTRv-amyloidosis,including the need for heart transplantation,and status of heart-liver transplantation are discussed.Results:Three patients needed a staged (1 patient) or simultaneous (2 patients) heart-liver transplant due to rapidly progressing cardiac failure and/or neurologic disability.Domino liver transplantation was impossible in two due to fibrotic hepatic transformation caused by cardiomyopathy.After a follow-up ranging from 3.5 to 9.5 years,cardiac (allograft) function was maintained in all patients,but neuropathy progressed in three patients,one of whom died after 80 months.Conclusions:This is the first report in (liver) transplant literature about the rare Val122del ATTRv muta-tion.Due to its aggressiveness,symptomatic patients should be prioritized on the liver and,in cases with cardiomyopathy,heart waiting lists in order to avoid the irreversible neurological and cardiac damage that leads to a rapid lethal outcome.